Abstract: Objective  To analyze the curative effect of oxcarbazepine suspension in treatment of infants (≤3 years old) with partial epilepsy and effect on immune function. Methods  One hundred and thirtyeight infants (≤ 3 years old) with partial epilepsy who received oxcarbazepine oral suspension treatment from May 2012 to January 2016 were chosen as observation group. The initial dosage was 8-10 mg/ (kg·d)， increased by 10 mg/(kg·d) every 7 days， the stable maintenance dose was 20-40 mg/(kg·d). Drug efficiency， complete control and adverse reactions were analyzed. Blood samples were taken from children before treatment and the third and sixth months after treatment. The children under 3 years old were selected as control group during the same period. Results  The complete control rate in the 13 months，4-6 months and 7-9 months after medication of the observation group was 41.48%， 44.44%  and 54.07%  and the total effective rate was 80.74%， 83.70% and 85.93%， respectively. Adverse reactions occurred in 25 cases with a rate of  18.52%. Before treatment， IgA， IgG， ICAM1， CD3+， CD4+ and CD8+ in  observation group were significantly different from those in  control group (P<0.05)， at 3，6 months after treatment， IgA， IgG， ICAM1，CD4+，CD8+ and CD3+ were significantly different from those before treatment (P<0.05). Conclusion  Oxcarbazepine oral suspension has good clinical effect in infants with partial epilepsy， not only can effectively reduce the frequency of seizures， but also can promote the normal immune state， and has less adverse reactions. The treatment compliance of children is better.

Key words: epilepsy, child, oxcarbazepine